# Alignment Healthcare, Inc.: financial statements, quarterly

ALHC · Nasdaq · CIK 1832466 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alhc.md) · [Financials](/companies/alhc/financials.md) · [Filings](/companies/alhc/filings.md) · [Insiders](/companies/alhc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alhc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [459 d](/filings/0000950170-24-021154.md) | [629](/filings/0001628280-25-021571.md) | [681](/filings/0001628280-25-036713.md) | [692](/filings/0001628280-25-047538.md) | [701 d](/filings/0001628280-26-012545.md) | [927](/filings/0001628280-26-028901.md) | [1,015](/filings/0001628280-26-051060.md) | [994](/filings/0001628280-26-068247.md) | [1,013 d](/filings/0001628280-26-012545.md) | [1,235](/filings/0001628280-26-028901.md) | [1,336](/filings/0001628280-26-051060.md) | [1,358](/filings/0001628280-26-068247.md) |
| Selling, general and administrative | $m | [83.7 d](/filings/0001628280-26-012545.md) | [90.5](/filings/0001628280-25-021571.md) | [87.9](/filings/0001628280-25-036713.md) | [90.9](/filings/0001628280-25-047538.md) | [102 d](/filings/0001628280-26-012545.md) | [104](/filings/0001628280-26-028901.md) | [104](/filings/0001628280-26-051060.md) | [110](/filings/0001628280-26-068247.md) | [126 d](/filings/0001628280-26-012545.md) | [121](/filings/0001628280-26-028901.md) | [131](/filings/0001628280-26-051060.md) | [136](/filings/0001628280-26-068247.md) |
| Operating income | $m | [(41.9) d](/filings/0001628280-26-012545.md) | [(41.1)](/filings/0001628280-25-021571.md) | [(18.4)](/filings/0001628280-25-036713.md) | [(19.5)](/filings/0001628280-25-047538.md) | [(22.5) d](/filings/0001628280-26-012545.md) | [(5.4)](/filings/0001628280-26-028901.md) | [22.7](/filings/0001628280-26-051060.md) | [7.7](/filings/0001628280-26-068247.md) | [(10.3) d](/filings/0001628280-26-012545.md) | [15.5](/filings/0001628280-26-028901.md) | [42.1](/filings/0001628280-26-051060.md) | [(3.8)](/filings/0001628280-26-068247.md) |
| Interest expense | $m | [5.5 d](/filings/0000950170-24-021154.md) | [5.4](/filings/0001628280-24-019994.md) | [5.7](/filings/0001628280-25-036713.md) | [6.9](/filings/0001628280-25-047538.md) | [5.5 d](/filings/0001628280-26-012545.md) | [4.0](/filings/0001628280-26-028901.md) | [4.0](/filings/0001628280-26-051060.md) | [4.0](/filings/0001628280-26-068247.md) | [3.9 d](/filings/0001628280-26-012545.md) | [4.1](/filings/0001628280-26-028901.md) | [4.3](/filings/0001628280-26-051060.md) | [4.3](/filings/0001628280-26-068247.md) |
| Income tax | $m | [(0.0) d](/filings/0001628280-26-012545.md) | [0.0](/filings/0001628280-25-021571.md) | [0.0](/filings/0001628280-25-036713.md) | [(0.0)](/filings/0001628280-25-047538.md) | [0.0 d](/filings/0001628280-26-012545.md) | [0.0](/filings/0001628280-26-028901.md) | [3.2](/filings/0001628280-26-051060.md) | [0.0](/filings/0001628280-26-068247.md) | [(3.2) d](/filings/0001628280-26-012545.md) | [0.0](/filings/0001628280-26-028901.md) | [1.3](/filings/0001628280-26-051060.md) | [(0.0)](/filings/0001628280-26-068247.md) |
| Net income | $m | [(47.2) d](/filings/0001628280-26-012545.md) | [(46.5)](/filings/0001628280-25-021571.md) | [(24.0)](/filings/0001628280-25-036713.md) | [(26.4)](/filings/0001628280-25-047538.md) | [(31.1) d](/filings/0001628280-26-012545.md) | [(9.1)](/filings/0001628280-26-028901.md) | [15.7](/filings/0001628280-26-051060.md) | [3.7](/filings/0001628280-26-068247.md) | [(11.0) d](/filings/0001628280-26-012545.md) | [11.4](/filings/0001628280-26-028901.md) | [36.6](/filings/0001628280-26-051060.md) | [(8.1)](/filings/0001628280-26-068247.md) |
| Diluted EPS | $ per share | not reported | [(0.25)](/filings/0001628280-25-021571.md) | [(0.13)](/filings/0001628280-25-036713.md) | [(0.14)](/filings/0001628280-25-047538.md) | not reported | [(0.05)](/filings/0001628280-26-028901.md) | [0.07](/filings/0001628280-26-051060.md) | [0.02](/filings/0001628280-26-068247.md) | not reported | [0.05](/filings/0001628280-26-028901.md) | [0.17](/filings/0001628280-26-051060.md) | [(0.04)](/filings/0001628280-26-068247.md) |
| Basic EPS | $ per share | not reported | [(0.25)](/filings/0001628280-25-021571.md) | [(0.13)](/filings/0001628280-25-036713.md) | [(0.14)](/filings/0001628280-25-047538.md) | not reported | [(0.05)](/filings/0001628280-26-028901.md) | [0.08](/filings/0001628280-26-051060.md) | [0.02](/filings/0001628280-26-068247.md) | not reported | [0.06](/filings/0001628280-26-028901.md) | [0.18](/filings/0001628280-26-051060.md) | [(0.04)](/filings/0001628280-26-068247.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [203](/filings/0001628280-26-012545.md) | [239](/filings/0001628280-25-021571.md) | [339](/filings/0001628280-25-036713.md) | [340](/filings/0001628280-25-047538.md) | [433](/filings/0001628280-26-012545.md) | [446](/filings/0001628280-26-028901.md) | [470](/filings/0001628280-26-051060.md) | [618](/filings/0001628280-26-068247.md) | [576](/filings/0001628280-26-068247.md) | [706](/filings/0001628280-26-028901.md) | [693](/filings/0001628280-26-051060.md) | [728](/filings/0001628280-26-068247.md) |
| Current assets | $m | [484](/filings/0001628280-25-008730.md) | [521](/filings/0001628280-24-019994.md) | [599](/filings/0001628280-24-034114.md) | [574](/filings/0001628280-24-044092.md) | [662](/filings/0001628280-26-012545.md) | [774](/filings/0001628280-25-021571.md) | [880](/filings/0001628280-25-036713.md) | [985](/filings/0001628280-25-047538.md) | [952](/filings/0001628280-26-068247.md) | [1,145](/filings/0001628280-26-028901.md) | [1,160](/filings/0001628280-26-051060.md) | [1,178](/filings/0001628280-26-068247.md) |
| Total assets | $m | [592](/filings/0001628280-25-008730.md) | [633](/filings/0001628280-24-019994.md) | [716](/filings/0001628280-24-034114.md) | [692](/filings/0001628280-24-044092.md) | [782](/filings/0001628280-26-012545.md) | [896](/filings/0001628280-25-021571.md) | [1,000](/filings/0001628280-25-036713.md) | [1,103](/filings/0001628280-25-047538.md) | [1,066](/filings/0001628280-26-068247.md) | [1,262](/filings/0001628280-26-028901.md) | [1,279](/filings/0001628280-26-051060.md) | [1,297](/filings/0001628280-26-068247.md) |
| Current liabilities | $m | [263](/filings/0001628280-25-008730.md) | [331](/filings/0001628280-24-019994.md) | [372](/filings/0001628280-24-034114.md) | [358](/filings/0001628280-24-044092.md) | [352](/filings/0001628280-26-012545.md) | [457](/filings/0001628280-25-021571.md) | [530](/filings/0001628280-25-036713.md) | [611](/filings/0001628280-25-047538.md) | [557](/filings/0001628280-26-068247.md) | [725](/filings/0001628280-26-028901.md) | [683](/filings/0001628280-26-051060.md) | [689](/filings/0001628280-26-068247.md) |
| Total liabilities | $m | [434](/filings/0001628280-25-008730.md) | [501](/filings/0001628280-24-019994.md) | [591](/filings/0001628280-24-034114.md) | [577](/filings/0001628280-24-044092.md) | [681](/filings/0001628280-26-012545.md) | [787](/filings/0001628280-25-021571.md) | [859](/filings/0001628280-25-036713.md) | [941](/filings/0001628280-25-047538.md) | [887](/filings/0001628280-26-068247.md) | [1,055](/filings/0001628280-26-028901.md) | [1,014](/filings/0001628280-26-051060.md) | [1,020](/filings/0001628280-26-068247.md) |
| Long-term debt | $m | [162](/filings/0001628280-25-008730.md) | [162](/filings/0001628280-24-019994.md) | [212](/filings/0001628280-24-034114.md) | [210](/filings/0001628280-24-044092.md) | [321](/filings/0001628280-26-012545.md) | [322](/filings/0001628280-25-021571.md) | [322](/filings/0001628280-25-036713.md) | [323](/filings/0001628280-25-047538.md) | [323](/filings/0001628280-26-068247.md) | [324](/filings/0001628280-26-028901.md) | [324](/filings/0001628280-26-051060.md) | [324](/filings/0001628280-26-068247.md) |
| Current portion of debt | $m | [0.0](/filings/0001628280-25-008730.md) | [0.0](/filings/0001628280-24-019994.md) | [0.0](/filings/0001628280-24-034114.md) | [1.6](/filings/0001628280-24-044092.md) | [0.0](/filings/0001628280-26-012545.md) | [0.0](/filings/0001628280-25-021571.md) | [0.0](/filings/0001628280-25-036713.md) | [0.0](/filings/0001628280-25-047538.md) | [0.0](/filings/0001628280-26-068247.md) | [0.0](/filings/0001628280-26-028901.md) | [0.0](/filings/0001628280-26-051060.md) | [0.0](/filings/0001628280-26-068247.md) |
| Shareholders' equity | $m | [157](/filings/0001628280-25-008730.md) | [131](/filings/0001628280-24-019994.md) | [124](/filings/0001628280-24-034114.md) | [115](/filings/0001628280-24-044092.md) | [99.9](/filings/0001628280-26-012545.md) | [108](/filings/0001628280-25-021571.md) | [141](/filings/0001628280-25-036713.md) | [162](/filings/0001628280-25-047538.md) | [179](/filings/0001628280-26-068247.md) | [207](/filings/0001628280-26-028901.md) | [265](/filings/0001628280-26-051060.md) | [277](/filings/0001628280-26-068247.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(187) d](/filings/0001628280-26-012545.md) | [(6.2)](/filings/0001628280-25-021571.md) | [23.5 d](/filings/0001628280-25-036713.md) | [26.2 d](/filings/0001628280-25-047538.md) | [(8.7) d](/filings/0001628280-26-012545.md) | [16.6](/filings/0001628280-26-028901.md) | [29.1 d](/filings/0001628280-26-051060.md) | [145 d](/filings/0001628280-26-068247.md) | [(50.4) d](/filings/0001628280-26-012545.md) | [129](/filings/0001628280-26-028901.md) | [(17.3) d](/filings/0001628280-26-051060.md) | [47.0 d](/filings/0001628280-26-068247.md) |
| Capital expenditure | $m | [10.6 d](/filings/0001628280-26-012545.md) | [11.1](/filings/0001628280-25-021571.md) | [11.7 d](/filings/0001628280-25-036713.md) | [9.3 d](/filings/0001628280-25-047538.md) | [9.3 d](/filings/0001628280-26-012545.md) | [8.3](/filings/0001628280-26-028901.md) | [8.0 d](/filings/0001628280-26-051060.md) | [5.5 d](/filings/0001628280-26-068247.md) | [5.0 d](/filings/0001628280-26-012545.md) | [7.4](/filings/0001628280-26-028901.md) | [10.1 d](/filings/0001628280-26-051060.md) | [8.4 d](/filings/0001628280-26-068247.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [183](/filings/0001628280-24-019994.md) | [186](/filings/0001628280-24-034114.md) | [187](/filings/0001628280-24-044092.md) | [189](/filings/0001628280-25-021571.md) | [191](/filings/0001628280-25-036713.md) | [191](/filings/0001628280-25-047538.md) | [194](/filings/0001628280-26-028901.md) | [210](/filings/0001628280-26-051060.md) | [209](/filings/0001628280-26-068247.md) | [213](/filings/0001628280-26-028901.md) | [215](/filings/0001628280-26-051060.md) | [209](/filings/0001628280-26-068247.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 209,268,394 at 2026-10-26, from the cover of the [10-Q filed 2026-10-29](/filings/0001628280-26-068247.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:01 ET. No prices; not investment advice.